BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38191874)

  • 21. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRD4 short isoform interacts with RRP1B, SIPA1 and components of the LINC complex at the inner face of the nuclear membrane.
    Alsarraj J; Faraji F; Geiger TR; Mattaini KR; Williams M; Wu J; Ha NH; Merlino T; Walker RC; Bosley AD; Xiao Z; Andresson T; Esposito D; Smithers N; Lugo D; Prinjha R; Day A; Crawford NP; Ozato K; Gardner K; Hunter KW
    PLoS One; 2013; 8(11):e80746. PubMed ID: 24260471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells.
    Nagarajan S; Bedi U; Budida A; Hamdan FH; Mishra VK; Najafova Z; Xie W; Alawi M; Indenbirken D; Knapp S; Chiang CM; Grundhoff A; Kari V; Scheel CH; Wegwitz F; Johnsen SA
    Nucleic Acids Res; 2017 Apr; 45(6):3130-3145. PubMed ID: 27980063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
    Ozer HG; El-Gamal D; Powell B; Hing ZA; Blachly JS; Harrington B; Mitchell S; Grieselhuber NR; Williams K; Lai TH; Alinari L; Baiocchi RA; Brinton L; Baskin E; Cannon M; Beaver L; Goettl VM; Lucas DM; Woyach JA; Sampath D; Lehman AM; Yu L; Zhang J; Ma Y; Zhang Y; Spevak W; Shi S; Severson P; Shellooe R; Carias H; Tsang G; Dong K; Ewing T; Marimuthu A; Tantoy C; Walters J; Sanftner L; Rezaei H; Nespi M; Matusow B; Habets G; Ibrahim P; Zhang C; Mathé EA; Bollag G; Byrd JC; Lapalombella R
    Cancer Discov; 2018 Apr; 8(4):458-477. PubMed ID: 29386193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.
    Shen C; Ipsaro JJ; Shi J; Milazzo JP; Wang E; Roe JS; Suzuki Y; Pappin DJ; Joshua-Tor L; Vakoc CR
    Mol Cell; 2015 Dec; 60(6):847-59. PubMed ID: 26626481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.
    Wu SY; Chiang CM
    J Biol Chem; 2007 May; 282(18):13141-5. PubMed ID: 17329240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic regulation of asymmetric cell division by the LIBR-BRD4 axis.
    Chen HF; Chang CT; Hsu KW; Peng PH; Lai JC; Hung MC; Wu KJ
    Nucleic Acids Res; 2024 Jan; 52(1):154-165. PubMed ID: 37986225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
    Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
    Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation.
    Yang F; Hu A; Guo Y; Wang J; Li D; Wang X; Jin S; Yuan B; Cai S; Zhou Y; Li Q; Chen G; Gao H; Zheng L; Tong Q
    Mol Cancer; 2021 Sep; 20(1):123. PubMed ID: 34579723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
    Wu X; Qi J; Bradner JE; Xiao G; Chen LF
    J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BET bromodomain proteins are required for glioblastoma cell proliferation.
    Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
    Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.
    Cooper JM; Patel AJ; Chen Z; Liao CP; Chen K; Mo J; Wang Y; Le LQ
    Clin Cancer Res; 2019 Jun; 25(11):3404-3416. PubMed ID: 30796033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High level of BRD4 promotes non-small cell lung cancer progression.
    Liao YF; Wu YB; Long X; Zhu SQ; Jin C; Xu JJ; Ding JY
    Oncotarget; 2016 Feb; 7(8):9491-500. PubMed ID: 26840017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation.
    Zheng B; Gold S; Iwanaszko M; Howard BC; Wang L; Shilatifard A
    Mol Cell; 2023 Aug; 83(16):2896-2910.e4. PubMed ID: 37442129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
    Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
    Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.
    Li X; Baek G; Ramanand SG; Sharp A; Gao Y; Yuan W; Welti J; Rodrigues DN; Dolling D; Figueiredo I; Sumanasuriya S; Crespo M; Aslam A; Li R; Yin Y; Mukherjee B; Kanchwala M; Hughes AM; Halsey WS; Chiang CM; Xing C; Raj GV; Burma S; de Bono J; Mani RS
    Cell Rep; 2018 Jan; 22(3):796-808. PubMed ID: 29346775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
    Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
    Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
    Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.